<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="767">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04400058</url>
  </required_header>
  <id_info>
    <org_study_id>GAM10-10</org_study_id>
    <nct_id>NCT04400058</nct_id>
  </id_info>
  <brief_title>Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression</brief_title>
  <official_title>Efficacy and Safety of Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to
      evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in
      patients with severe Coronavirus disease
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stabilization or Improvement in Clinical Status</measure>
    <time_frame>7 days</time_frame>
    <description>Proportion of subjects with stabilized or improved clinical status at Day 7 on at least one category on a 6-point clinical status scale.
Clinical status categories will be defined as:
Hospital discharge or meet discharge criteria (discharge criteria are defined as clinical recovery, i.e. fever, respiratory rate, oxygen saturation return to normal, and cough relief).
Hospitalization, not requiring supplemental oxygen.
Hospitalization, requiring supplemental oxygen (but not NIV/HFNC).
ICU/hospitalization, requiring NIV/HFNC therapy.
ICU, requiring Extracorporeal Membrane Oxygenation (ECMO) and/or IMV.
Death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive Clinical Status Analysis</measure>
    <time_frame>7 days</time_frame>
    <description>Change from Baseline (Day 1) at Day 7 in terms of the 6-point clinical status scale (descriptive analysis).
Clinical status categories will be defined as:
Hospital discharge or meet discharge criteria (discharge criteria are defined as clinical recovery, i.e. fever, respiratory rate, oxygen saturation return to normal, and cough relief).
Hospitalization, not requiring supplemental oxygen.
Hospitalization, requiring supplemental oxygen (but not NIV/HFNC).
ICU/hospitalization, requiring NIV/HFNC therapy.
ICU, requiring Extracorporeal Membrane Oxygenation (ECMO) and/or IMV.
Death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Status Assessment</measure>
    <time_frame>14 days</time_frame>
    <description>Proportion of subjects with maintenance or improvement by at least one category on the 6-point clinical status scale on Day 14. (This endpoint will go into formal hypothesis testing procedure)
Clinical status categories will be defined as:
Hospital discharge or meet discharge criteria (discharge criteria are defined as clinical recovery, i.e. fever, respiratory rate, oxygen saturation return to normal, and cough relief).
Hospitalization, not requiring supplemental oxygen.
Hospitalization, requiring supplemental oxygen (but not NIV/HFNC).
ICU/hospitalization, requiring NIV/HFNC therapy.
ICU, requiring Extracorporeal Membrane Oxygenation (ECMO) and/or IMV.
Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Time to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical Ventilation Initiation</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Proportion of subjects requiring invasive mechanical ventilation by Day 33.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical Ventilation Duration</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Duration of invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 Test Result</measure>
    <time_frame>7 days</time_frame>
    <description>Results of RT-PCR for SARS-CoV-2 from nares/throat swab and/or sputum and/or lower respiratory tract sample on Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all AEs</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Incidence of all AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs considered related to the IMP</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Incidence of AEs considered related to the IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Incidence of serious adverse events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological findings (chest CT/chest X-ray)</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>Radiological findings (chest CT/chest X-ray)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose</measure>
    <time_frame>Up to 33 daya</time_frame>
    <description>Change from baseline in blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood calcium</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in blood calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbon dioxide</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in carbon dioxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chloride</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in chloride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total protein</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in total protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in alkaline phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine transaminase</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in alanine transaminase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in aspartate aminotransferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood urea nitrogen</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in blood urea nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in D-dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in fibrinogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PT</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in PT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTT</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in PTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in INR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in hsCRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDH</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in LDH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in IgG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgM</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in IgM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgA</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in IgA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IFE</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in IFE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in troponin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell count</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in red blood cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in hemoglobjn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in mean corpuscular volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in mean corpuscular hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular hemoglobin concentration</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in mean corpuscular hemoglobin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red cell distribution width</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in red cell distribution width</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell count</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in white blood cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell differential</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in white blood cell differential</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in platelet count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean platelet volume</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in mean platelet volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet distribution width</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in platelet distribution width</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in SpO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A-a gradient</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in A-a gradient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in pulse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiration Rate</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in respiration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Change from baseline in body temperature</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Octagam 10%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octagam 10%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octagam 10%</intervention_name>
    <description>Octagam 10%, 2 g/kg divided by 4 days (0.5 g/kg/day), administered by intravenous infusion over approximately 2 hours per day over 4 consecutive days</description>
    <arm_group_label>Octagam 10%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult aged ≥18years old

          2. Provide voluntary, fully informed written and signed consent before any study-related
             procedures are conducted

          3. Able to understand and comply with the relevant aspects of the study protocol

          4. Laboratory (RT-PCR) confirmed COVID-19 infection on throat swab and/or sputum and/or
             lower respiratory tract samples

          5. Hospitalized with a resting room-air SpO2 of ≤93% or PaO2/FiO2 ratio &lt;300mmHg.
             Measurement can be taken from documented source records in the 24 hours prior to
             screening

          6. Chest imaging confirming lung involvement

        Exclusion Criteria:

          1. Existence of other evidence that can explain pneumonia including but not limited to:
             Influenza A virus, influenza B virus, bacterial pneumonia, known fungal pneumonia,
             suspected fungal pneumonia based on compromised immune system with a history of past
             fungal infections, noninfectious causes, etc.

          2. Known history of serious allergic reactions, including anaphylaxis, to IVIG or its
             preparation components

          3. Subjects with a history of thromboembolic event (TEE) within the last 12 months, such
             as deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke,
             transient ischemic attack, peripheral artery disease (Fontaine IV)

          4. Subjects with an underlying medical condition that can lead to hypercoagulable states
             and hyperviscosity such as antithrombin III deficiency, Factor V Leiden, Protein C
             deficiency, antiphospholipid syndrome and malignancy

          5. Known history of selective IgA deficiency with antibodies against IgA

          6. Subjects with conditions such as human immunodeficiency virus (HIV) infection, known
             acute or chronic hepatitis B or C (HBsAg positive or HCV RNA PCR positive or currently
             treated with antivirals), pulmonary fibrosis, elevated procalcitonin (&gt; 0.5) with
             concomitant neutrophilia (elevated polys), heparin induced thrombocytopenia (HIT), and
             moderate to severe renal dysfunction (per investigator discretion based on glomerular
             filtration rate [GFR] &lt;15 mL/min/1.73 m2 to 59 mL/ min/1.73 m2, as defined by KDIGO
             Clinical Practice Guideline)&lt;15mL/min/1.73 m2 to 59mL/min/1.73 m2, as defined by KDIGO
             Clinical Practice Guideline)

          7. Currently requiring IMV (invasive mechanical ventilation or having received IMV during
             the last 30 days

          8. Known clinically significant preexisting lung, heart, or neuromuscular disease that,
             in the investigator's opinion, would impact subject's ability to complete study or may
             confound the study results

          9. Women who are pregnant or breast-feeding

         10. Subjects who received COVID-19 convalescent plasma, IVIG products, anti-interleukin
             agents (eg Tocilizumab), or interferons for their COVID-19 disease before enrolment or
             plan to receive this treatment during the course of the study

         11. Enrolled in other experimental studies or taking experimental medications (ie,
             convalescent plasma)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikaela Raymond</last_name>
    <phone>8663371868</phone>
    <email>ctgov@clinicalresearchmgt.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

